Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.

Arteriosclerosis, thrombosis, and vascular biology - 1 Jun 2016

Yaoita Nobuhiro, Satoh Kimio, Satoh Taijyu, Sugimura Koichiro, Tatebe Shunsuke, Yamamoto Saori, Aoki Tatsuo, Miura Masanobu, Miyata Satoshi, Kawamura Takeshi, Horiuchi Hisanori, Fukumoto Yoshihiro, Shimokawa Hiroaki

Abstract excerpt

OBJECTIVE: The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) remains to be elucidated. Thrombin-activatable fibrinolysis inhibitor (TAFI) inhibits fibrinolysis. It remains to be elucidated whether TAFI is directly involved in the pathogenesis of CTEPH. We examined potential involvement of TAFI in the pathogenesis of CTEPH in humans. APPROACH AND RESULTS: We enrolled 68 consecutive patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation Tests
Share to Blood Platelets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboxypeptidase B2

Share to Cardiac Catheterization

Share to Fibrinolysis

Share to Hypertension, Pulmonary

Share to Protease Inhibitors

Share to Pulmonary Embolism

Source

Identifiers

PMID: 27102961
DOI: 10.1161/ATVBAHA.115.306845

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.PMID 27102961Read ↗

Fibrinogen Aα Thr312Ala polymorphism specifically contributes to chronic thromboembolic pulmonary hypertension by increasing fibrin resistance.Semantic proximity Read ↗

The role of endothelial cell function in regulating fibrinolysis and the development and progression of thromboembolic pulmonary hypertensionSemantic proximity Read ↗

Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hypertension.Semantic proximity Read ↗

Targeting pathogenic VWF/ADAMTS13 dysregulation attenuates CTEPH progressionSemantic proximity Read ↗

Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.Semantic proximity Read ↗

Do Hemodynamic Definitions of Chronic Thromboembolic Pulmonary Hypertension Distinguish between Distinct Phenotypes of Chronic Thromboembolic Pulmonary Disease?Semantic proximity Read ↗

Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis.Semantic proximity Read ↗

From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.Semantic proximity Read ↗

Cellular, Molecular, and Enzymatic Signatures of Thrombi are Vascular Bed-DependentSemantic proximity Read ↗

Thrombectomy for pulmonary embolism under general anesthesia and cardiopulmonary bypass: a case reportSemantic proximity Read ↗

Thrombophilia and pulmonary endarterectomy.Semantic proximity Read ↗

Association of chronic thromboembolic pulmonary hypertension with hereditary and acquired risk factors for thromboembolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.